Shots: The application is based on two studies i.e P-III EINSTEIN-Jr & UNIVERSE. The P-III EINSTEIN-Jr study evaluates Xarelto in 500 children in a ratio (2:1) aged birth to 17yrs. […]readmore
Tags : Venous Thromboembolism
Shots: Bayer has submitted MAA to EMA based on P-III EINSTEIN-Jr. study evaluating Rivaroxaban vs SOC in 500 children in a ratio (2:1) aged from birth to 17yrs. with documented […]readmore
Shots: The approval is based on P-III MAGELLAN study assessing Xarelto in preventing VTE in patients with acute medical illnesses, at risk for thromboembolic complications who are not at high […]readmore
Shots: The P-IIb/III DIVERSITY study involve assessing of Pradaxa vs SOC (heparin or vitamin K antagonist) in children with acute VTE requiring anticoagulation therapy for 3mos. aged ≤18yrs. resulted in […]readmore